CN114364380A - (s)-2-((2s,3r)-1-氨基-3-羟基-1-氧代丁烷-2-基)-1-氧代-2,5-二氮杂螺[3.4]辛烷-5-甲酸叔丁酯的固体形式及其制备方法 - Google Patents

(s)-2-((2s,3r)-1-氨基-3-羟基-1-氧代丁烷-2-基)-1-氧代-2,5-二氮杂螺[3.4]辛烷-5-甲酸叔丁酯的固体形式及其制备方法 Download PDF

Info

Publication number
CN114364380A
CN114364380A CN202080059974.0A CN202080059974A CN114364380A CN 114364380 A CN114364380 A CN 114364380A CN 202080059974 A CN202080059974 A CN 202080059974A CN 114364380 A CN114364380 A CN 114364380A
Authority
CN
China
Prior art keywords
crystalline form
compound
peaks
solid
solid crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080059974.0A
Other languages
English (en)
Chinese (zh)
Inventor
袁晓达
冯少新
丹尼·T·迪恩
威廉·R·佩劳特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naurex Inc
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of CN114364380A publication Critical patent/CN114364380A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080059974.0A 2019-06-24 2020-06-23 (s)-2-((2s,3r)-1-氨基-3-羟基-1-氧代丁烷-2-基)-1-氧代-2,5-二氮杂螺[3.4]辛烷-5-甲酸叔丁酯的固体形式及其制备方法 Pending CN114364380A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24
US62/865,826 2019-06-24
PCT/US2020/039163 WO2020263847A1 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Publications (1)

Publication Number Publication Date
CN114364380A true CN114364380A (zh) 2022-04-15

Family

ID=74060350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080059974.0A Pending CN114364380A (zh) 2019-06-24 2020-06-23 (s)-2-((2s,3r)-1-氨基-3-羟基-1-氧代丁烷-2-基)-1-氧代-2,5-二氮杂螺[3.4]辛烷-5-甲酸叔丁酯的固体形式及其制备方法

Country Status (11)

Country Link
US (1) US20220267341A1 (https=)
EP (1) EP3986399A4 (https=)
JP (2) JP7617043B2 (https=)
CN (1) CN114364380A (https=)
AU (1) AU2020304001B2 (https=)
BR (1) BR112021026380A2 (https=)
CA (1) CA3144600A1 (https=)
IL (1) IL289198A (https=)
MA (1) MA56550A (https=)
MX (2) MX2022000069A (https=)
WO (1) WO2020263847A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269338A (zh) * 2019-06-24 2022-04-01 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863804A (zh) * 2003-10-03 2006-11-15 诺瓦提斯公司 某些取代的螺环内酰胺及其作为药物的用途
CN101243056A (zh) * 2005-06-21 2008-08-13 味之素株式会社 苯基丙氨酸衍生物的结晶、其制备方法及其应用
CN105229011A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2017172565A1 (en) * 2016-03-28 2017-10-05 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
CN109415372A (zh) * 2016-05-19 2019-03-01 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2020263848A1 (en) * 2019-06-24 2020-12-30 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US9758525B2 (en) * 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863804A (zh) * 2003-10-03 2006-11-15 诺瓦提斯公司 某些取代的螺环内酰胺及其作为药物的用途
CN101243056A (zh) * 2005-06-21 2008-08-13 味之素株式会社 苯基丙氨酸衍生物的结晶、其制备方法及其应用
CN105229011A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2017172565A1 (en) * 2016-03-28 2017-10-05 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
CN109415372A (zh) * 2016-05-19 2019-03-01 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2020263848A1 (en) * 2019-06-24 2020-12-30 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds
CN114269338A (zh) * 2019-06-24 2022-04-01 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEFFREY S BURGDORF，等: "Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects", INT J NEUROPSYCHOPHARMACOL ., vol. 25, no. 12, 12 December 2022 (2022-12-12), pages 979 - 991 *
刘胜高，等: "雷贝拉唑钠的成盐、结晶", 齐鲁药事 ., vol. 27, no. 11, 30 November 2008 (2008-11-30), pages 685 - 687 *
李毓飞;张明;张豪;廖琦;边煦霏;王天宝;胡湘南;: "(S)-1-[2-(3-羟基金刚烷-1-氨基)乙酰基]吡咯烷-2-甲酰胺的合成", 化学研究与应用, no. 11, 15 November 2018 (2018-11-15), pages 76 - 81 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269338A (zh) * 2019-06-24 2022-04-01 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体
CN114269338B (zh) * 2019-06-24 2025-02-18 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体

Also Published As

Publication number Publication date
WO2020263847A1 (en) 2020-12-30
AU2020304001B2 (en) 2026-04-09
JP2025069143A (ja) 2025-04-30
MX2022000069A (es) 2022-05-24
MA56550A (fr) 2022-04-27
US20220267341A1 (en) 2022-08-25
KR20220061088A (ko) 2022-05-12
CA3144600A1 (en) 2020-12-30
EP3986399A4 (en) 2023-06-07
JP7617043B2 (ja) 2025-01-17
JP2022539342A (ja) 2022-09-08
IL289198A (en) 2022-02-01
AU2020304001A1 (en) 2022-01-27
MX2025002579A (es) 2025-04-02
BR112021026380A2 (pt) 2022-05-10
EP3986399A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
US11472773B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP6471103B2 (ja) ヒスタミンｈ４受容体のベンゾイミダゾール−２−イルピリミジンモジュレータ
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
US11584715B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
JP2025069143A (ja) ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
WO2014000719A1 (en) Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
KR102958083B1 (ko) 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
KR20260061467A (ko) 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
WO2012125993A1 (en) Solid state forms of rilpivirine base, and rilipivirine salts
EA044016B1 (ru) Твердые формы трет-бутил(s)-2-((2s,3r)-1-амино-3-гидрокси-1-оксобутан-2-ил)-1-оксо-2,5-диазаспиро[3.4]октан-5-карбоксилата и способы их получения
WO2021100730A1 (ja) ピロリジン化合物の製造方法
JP7519376B2 (ja) ロスバスタチンカルシウム塩の製造方法
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
AU2024316640A1 (en) Process of making 2-[(3r)-2-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile and solvate forms thereof
CA2902436C (en) Salt of omecamtiv mecarbil and process for preparing salt
TW202332440A (zh) 神經激肽-1拮抗劑前藥化合物的晶型
KR20250085608A (ko) 1-((3S,4R)-3-((2-((1-에틸-1H-피라졸-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)옥시)-4-플루오로피페리딘-1-일)프로프-2-엔-1-온의인산염, 이의 결정형 및 이의 제조 방법
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
HK40035144B (zh) 两种化合物的制备方法
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt
JP2012500192A (ja) １−イソプロピル−４−｛［４−（テトラヒドロ−２ｈ−ピラン−４−イルオキシ）フェニル］カルボニル｝ヘキサヒドロ−１ｈ−１，４−ジアゼピンの塩およびその調製方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination